Annals of Hematology

, Volume 87, Issue 9, pp 717–726 | Cite as

Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone)

  • Carsten Zwick
  • Josef Birkmann
  • Norma Peter
  • Heinrich Bodenstein
  • Roland Fuchs
  • Mathias Hänel
  • Marcel Reiser
  • Manfred Hensel
  • Michael Clemens
  • Samira Zeynalova
  • Marita Ziepert
  • Michael Pfreundschuh
Original Article

Abstract

To compare toxicity of etoposide bolus with continuous infusion and to assess the efficacy of the CEMP (cisplatinum, etoposide, mitoxantrone, prednisone) regimen, 47 patients with refractory or relapsed aggressive non-Hodgkin’s lymphoma older than 60 years (n = 43) or not qualifying for high-dose chemotherapy (n = 4) received five four-weekly CEMP cycles. Patients were randomised to start with bolus or continuous-infusion etoposide and then received bolus and infusional etoposide in an alternating fashion. The primary objective was the comparison of differences in the course of leukocytopenia and thrombocytopenia between the two application schedules. CEMP was well tolerated with little organ and moderate haematotoxicity. There was no difference in toxicity between bolus and continuous-infusion etoposide. Complete remission rate was 44% in patients relapsing ≥1 year, 27% in patients relapsing within the first year after achieving complete remission and 5% in primary refractory patients. Median event-free and overall survivals for all patients were 3 and 10 months, respectively. The observed equitoxicity and the more challenging logistics of a 60-h infusion make bolus injection the preferred application of etoposide. As the CEMP regimen is well tolerated and efficacious in elderly patients with relapsed or refractory aggressive non-Hodgkin’s lymphoma for whom more aggressive therapies are not feasible, a three-weekly modification of CEMP should be tested in combination with rituximab.

Keywords

Aggressive lymphoma Chemotherapy Continuous infusion Relapse 

Notes

Acknowledgements

This study was supported by Deutsche Krebshilfe. Data management: B. Mann, A. Schöler, U. Schönwiese, L. Martin Montanez, and W. Beck, M. Kunert, B. Wicklein. Statistical analysis: M. Löffler, M. Klöss, S. Zeynalova, D. Hasenclever. The following investigators and institutions recruited patients for this study: Hans-Jürgen Bias (Kreiskrankenhaus Waldbröl), Josef Birkmann (Klinikum Nürnberg), Heinrich Bodenstein (Klinikum Minden), Hermann Einsele (Universitätsklinik Würzburg), Ludwig Fischer von Weikersthal (Klinikum St. Marien Amberg), Roland Fuchs (St.-Antonius-Hospital Eschweiler), Johannes Grossmann (Evangelisches Krankenhaus Bethesda Mönchengladbach), Mathias Hänel (Klinikum Chemnitz), Martin Hoffmann (Klinikum der Stadt Ludwigshafen), Christian Kölbel (Krankenhaus der Barmherzigen Brüder Trier), Wilhelm Koch (Leopoldina-Krankenhaus Schweinfurt), Beate Krammer-Steiner (Klinikum Rostock Südstadt), Christiane Lange (Kliniken Maria Hilf, Krankenhaus St. Franziskus Mönchengladbach), Werner Langer (Kreiskrankenhaus Aurich), Walter Lindemann (Katholisches Krankenhaus Hagen), Peter Norbert Meier (Henriettenstift Hannover), Hans-Günther Mergenthaler (Katharinenhospital Stuttgart), Frank Odemar (Klinikum Bernburg), Roland Paliege (Klinikum Bad Hersfeld), Norma Peter (Carl-Thiem-Klinikum Cottbus), Michael Pfreundschuh (Universitätsklinikum des Saarlandes Homburg), Wolff Schmiegel (Universitätsklinik Bochum), Michael Schöttler (Martin-Luther-Krankenhaus Schleswig), Theo Scholten (Allgemeines Krankenhaus Hagen), Ulrich Stark (St.-Agnes-Hospital Bocholt), Frank Tympner (Kreiskrankenhaus Neumarkt).

References

  1. 1.
    Alberts DS, Peng YM, Bowden GT, Dalton WS, Mackel C (1985) Pharmacology of mitoxantrone: mode of action and pharmacokinetics. Invest New Drugs 3:101–107PubMedGoogle Scholar
  2. 2.
    Cabanillas F, Hagemeister FB, Bodey GP, Freireich EJ (1982) IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 60:693–697PubMedGoogle Scholar
  3. 3.
    Chao NJ, Rosenberg SA, Horning SJ (1990) CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin’s lymphoma. Blood 76:1293–1298PubMedGoogle Scholar
  4. 4.
    Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244PubMedGoogle Scholar
  5. 5.
    Child JA, Johnson SA, Rule S, Smith GM, Morgan GJ, Johnson PW, Prentice AG, Tollerfield SM, Wareham E (2000) FLUDAP: salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma 37:309–317PubMedGoogle Scholar
  6. 6.
    Clark PI, Slevin ML, Joel SP, Osborne RJ, Talbot DI, Johnson PW, Reznek R, Masud T, Gregory W, Wrigley PF (1994) A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. J Clin Oncol 12(7):1427–1435PubMedGoogle Scholar
  7. 7.
    Crump M, Baetz T, Couban S, Belch A, Marcellus D, Howson-Jan K, Imrie K, Myers R, Adams G, Ding K, Paul N, Shepherd L, Iglesias J, Meyer R (2004) Gemcitabine, dexamethasone and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer 101:1835–1842PubMedCrossRefGoogle Scholar
  8. 8.
    Crump M, Couban S, Meyer R, Rudinskas L, Zanke B, Gluck S, Maksymiuk A, Hoskins P, Matthews S, Eisenhauer E (2002) Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin’s lymphoma: a National Cancer Institute of Canada Clinical Trials Group study. Leuk Lymphoma 43:1581–1587PubMedCrossRefGoogle Scholar
  9. 9.
    De Lord C, Newland AC, Linch DC, Vaughan HB, Vaughan HG (1992) Failure of IMVP-16 as second-line treatment for relapsed or refractory high grade non-Hodgkin’s lymphoma. Hematol Oncol 10:81–86PubMedCrossRefGoogle Scholar
  10. 10.
    Drewinko M, Barlogie B (1976) Survival and cell cycle progression delay of human lymphoma cells in vitro exposed to VP-16. Cancer Treat Rep 60:1295–1306PubMedGoogle Scholar
  11. 11.
    El Gnaoui T, Dupuis J, Joly B, Belhadj K, Rahmouni A, Copie-Bergman C, Allain A, Tabah-Fisch I, Reyes F, Haioun C (2005) Rituximab, gemcitabine and oxaliplatin (R-GEMOX): a promising regimen for refractory/relapsed B-cell lymphoma, a single institution pilot study. (abstract). Ann Oncol 15(Supplement 5):182Google Scholar
  12. 12.
    Enblad G, Hagberg H, Glimelius B (1996) Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for non-Hodgkin’s lymphomas: a Swedish national prospective study. Swedish Lymphoma Study Group. Acta Oncol 35:165–170PubMedCrossRefGoogle Scholar
  13. 13.
    Ezzat AA, Khalifa F, Berry J, Khan B, Raja MA, Abdel-Warith A (1994) E-SHAP: an effective treatment in selected patients with relapsed non-Hodgkin’s lymphoma. Ann Oncol 5:453–456PubMedGoogle Scholar
  14. 14.
    Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA, Miller TP (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 328:1002–1006PubMedCrossRefGoogle Scholar
  15. 15.
    Girouard C, Dufresne J, Imrie K, Stewart AK, Brandwein J, Prince HM, Pantolony D, Keating A, Crump M (1997) Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin’s lymphoma prior to autologous bone marrow transplantation. Ann Oncol 8:675–680PubMedCrossRefGoogle Scholar
  16. 16.
    Gutierrez M, Chabner BA, Pearson D, Steinberg SM, Jaffe ES, Cheson BD, Fojo A, Wilson WH (2000) Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol 18:3633–3642PubMedGoogle Scholar
  17. 17.
    Haim N, Ben Shahar M, Faraggi D, Tsuri-Etzioni A, Leviov M, Epelbaum R (1997) Dexamethasone, etoposide, ifosfamide, and cisplatin as second-line therapy in patients with aggressive non-Hodgkin’s lymphoma. Cancer 80:1989–1996PubMedCrossRefGoogle Scholar
  18. 18.
    Hanel M, Kroger N, Sonnenberg S, Bornhauser M, Kruger W, Kroschinsky F, Hanel A, Metzner B, Birkmann J, Schmid B, Hoffknecht MM, Fiedler F, Ehninger G, Zander AR (2002) Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma. Ann Hematol 81:96–102PubMedCrossRefGoogle Scholar
  19. 19.
    Haq R, Sawka CA, Franssen E, Berinstein NL (1999) Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma 35:527–536PubMedCrossRefGoogle Scholar
  20. 20.
    Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting—Airlie House, Virginia, November 1997. J Clin Oncol 17:3835–3849PubMedGoogle Scholar
  21. 21.
    Hill BT, Whelan RD, Rupniak HT, Dennis LY, Rosholt MA (1981) A comparative assessment of the in vitro effects of drugs on cells by means of colony assays or flow microfluorimetry. Cancer Chemother Pharmacol 7:21–26PubMedCrossRefGoogle Scholar
  22. 22.
    Hill BT, Dennis LY, Li XT, Whelan RD (1985) Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro. Cancer Chemother Pharmacol 14:194–201PubMedCrossRefGoogle Scholar
  23. 23.
    Kaplan EL, Meier R (1958) Nonparametric estimation from incomplete observations. (abstract). J Am Stat Assoc 53:457–481CrossRefGoogle Scholar
  24. 24.
    Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, Rosenberg SA, Coltman CA, Tubiana M (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 7:1630–1636PubMedGoogle Scholar
  25. 25.
    Ludwig R, Alberts DS, Miller TP, Salmon SE (1984) Evaluation of anticancer drug schedule dependency using an in vitro human tumor clonogenic assay. Cancer Chemother Pharmacol 12(3):135–141PubMedGoogle Scholar
  26. 26.
    Martelli M, Vignetti M, Zinzani PL, Gherlinzoni F, Meloni G, Fiacchini M, Papa G, Martelli MF, Calabresi F, Tura S, Mandelli F (1996) High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin’s lymphoma with partial response to front-line chemotherapy: a prospective randomized Italian multicenter study. J Clin Oncol 14:534–542PubMedGoogle Scholar
  27. 27.
    McKelvey EM, Gottlieb JA, Wilson HE, Haut A, Talley RW, Stephens R, Lane M, Gamble JF, Jones SE, Grozea PN, Gutterman J, Coltman C, Moon TE (1976) Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer 38:1484–1493PubMedCrossRefGoogle Scholar
  28. 28.
    Mey UJ, Olivieri A, Orlopp KS, Rabe C, Strehl JW, Gorschlueter M, Hensel M, Flieger D, Glasmacher AG, Schmidt-Wolf IG (2006) DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis. Leuk Lymphoma 47:2558–2566PubMedCrossRefGoogle Scholar
  29. 29.
    Mey UJ, Orlopp KS, Flieger D, Strehl JW, Ho AD, Hensel M, Bopp C, Gorschluter M, Wilhelm M, Birkmann J, Kaiser U, Neubauer A, Florschutz A, Rabe C, Hahn C, Glasmacher AG, Schmidt-Wolf IG (2006) Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin’s lymphoma. Cancer Invest 24:593–600PubMedCrossRefGoogle Scholar
  30. 30.
    Meyer RM, Hryniuk WM, Goodyear MD (1991) The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin’s lymphoma. J Clin Oncol 9:339–347PubMedGoogle Scholar
  31. 31.
    Moskowitz CH, Bertino JR, Glassman JR, Hedrick EE, Hunte S, Coady-Lyons N, Agus DB, Goy A, Jurcic J, Noy A, O’Brien J, Portlock CS, Straus DS, Childs B, Frank R, Yahalom J, Filippa D, Louie D, Nimer SD, Zelenetz AD (1999) Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin’s lymphoma. J Clin Oncol 17:3776–3785PubMedGoogle Scholar
  32. 32.
    Nuckel H, Durig J, Duhrsen U (2003) Salvage chemotherapy according to the ASHAP protocol: a single-center study of 24 patients with relapsed or refractory aggressive non-Hodgkin’s lymphomas. Ann Hematol 82:481–486PubMedCrossRefGoogle Scholar
  33. 33.
    Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rube C, Rudolph C, Reiser M, Hossfeld DK, Eimermacher H, Hasenclever D, Schmitz N, Loeffler M (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104:634–641PubMedCrossRefGoogle Scholar
  34. 34.
    Philip T, Guglielmi C, Hagenbeek A, Somers R, van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 333:1540–1545PubMedCrossRefGoogle Scholar
  35. 35.
    Press OW, Livingston R, Mortimer J, Collin C, Appelbaum F (1991) Treatment of relapsed non-Hodgkin’s lymphomas with dexamethasone, high- dose cytarabine, and cisplatin before marrow transplantation. J Clin Oncol 9:423–431PubMedGoogle Scholar
  36. 36.
    Reiser M, Josting A, Dias WP, Draube A, Scheid C, Tesch H, Wolf J, Diehl V, Engert A (1999) Dexa-BEAM is not effective in patients with relapsed or resistant aggressive high-grade non-Hodgkin’s lymphoma. Leuk Lymphoma 33:305–312PubMedGoogle Scholar
  37. 37.
    Rodriguez MA, Cabanillas FC, Velasquez W, Hagemeister FB, McLaughlin P, Swan F, Romaguera JE (1995) Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol 13:1734–1741PubMedGoogle Scholar
  38. 38.
    Rodriguez-Monge EJ, Cabanillas F (1997) Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience. Hematol Oncol Clin North Am 11:937–947PubMedCrossRefGoogle Scholar
  39. 39.
    Rybak ME, McCarroll K, Kaplan RJ, Propert KJ, Budman DR, Gottlieb AJ (1990) Phase II trial of etoposide and cis-diaminodichloro-platinum in patients with refractory and relapsed Hodgkin’s disease: Cancer and Leukemia Group B (CALGB) Study 8353. Med Pediatr Oncol 18:177–180PubMedCrossRefGoogle Scholar
  40. 40.
    Seymour JF, Grigg AP, Szer J, Fox RM (2002) Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin’s lymphoma. Cancer 94:585–593PubMedCrossRefGoogle Scholar
  41. 41.
    Slevin ML, Clark PI, Joel SP, Malik S, Osborne RJ, Gregoray WM, Lowe DG, Reznek RH, Wrigley PF (1989) A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 7(9):1333–1340PubMedGoogle Scholar
  42. 42.
    Soussain C, Souleau B, Gabarre J, Zouabi H, Sutton L, Boccaccio C, Albin N, Charlotte F, Merle-Beral H, Delort J, Binet JL, Leblond V (1999) Intensive chemotherapy with hematopoietic cell transplantation after ESHAP therapy for relapsed or refractory non-Hodgkin’s lymphoma. Results of a single-centre study of 65 patients. Leuk Lymphoma 33:543–550PubMedGoogle Scholar
  43. 43.
    Sparano JA, Wiernik PH, Leaf A, Dutcher JP (1993) Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin’s lymphoma: evidence for a schedule-dependent effect favoring infusional administration of chemotherapy. J Clin Oncol 11:1071–1079PubMedGoogle Scholar
  44. 44.
    Sweetenham JW, Johnson PW (1994) ESHAP chemotherapy for relapsed/refractory non-Hodgkin’s lymphoma. J Clin Oncol 12:2766PubMedGoogle Scholar
  45. 45.
    Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, Jagannath S, Hagemeister FB, Redman JR, Swan F (1988) Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 71:117–122PubMedGoogle Scholar
  46. 46.
    Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, Romaguera J, Rubenstein E, Cabanillas F (1994) ESHAP—an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 12:1169–1176PubMedGoogle Scholar
  47. 47.
    Wilson WH, Bryant G, Bates S, Fojo A, Wittes RE, Steinberg SM, Kohler DR, Jaffe ES, Herdt J, Cheson BD (1993) EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin’s lymphoma. J Clin Oncol 11:1573–1582PubMedGoogle Scholar
  48. 48.
    Wilson WH, Grossbard ML, Pittaluga S, Cole D, Pearson D, Drbohlav N, Steinberg SM, Little RF, Janik J, Gutierrez M, Raffeld M, Staudt L, Cheson BD, Longo DL, Harris N, Jaffe ES, Chabner BA, Wittes R, Balis F (2002) Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood 99:2685–2693PubMedCrossRefGoogle Scholar
  49. 49.
    Wilson WH, Gutierrez M, O’Connor P, Frankel S, Jaffe E, Chabner BA, Grossbard ML (2002) The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R. Semin Oncol 29:41–47PubMedCrossRefGoogle Scholar
  50. 50.
    Yap HY, Blumenschein GR, Schell FC, Buzdar AU, Valdivieso M, Bodey GP (1981) Dihydroxyanthracenedione: a promising new drug in the treatment of metastatic breast cancer. Ann Intern Med 95:694–697PubMedGoogle Scholar
  51. 51.
    Zelenetz AD, Hamlin P, Kewalramani T, Yahalom J, Nimer S, Moskowitz CH (2003) Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin’s lymphoma. Ann Oncol 14(Suppl 1):I5–I10PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Carsten Zwick
    • 1
  • Josef Birkmann
    • 2
  • Norma Peter
    • 3
  • Heinrich Bodenstein
    • 4
  • Roland Fuchs
    • 5
  • Mathias Hänel
    • 6
  • Marcel Reiser
    • 7
  • Manfred Hensel
    • 8
  • Michael Clemens
    • 9
  • Samira Zeynalova
    • 10
  • Marita Ziepert
    • 10
  • Michael Pfreundschuh
    • 1
    • 11
  1. 1.Innere Medizin IUniversitätskliniken des SaarlandesHomburgGermany
  2. 2.Medizinische Klinik VKlinikum NürnbergNürnbergGermany
  3. 3.Carl-Thiem-Klinikum CottbusCottbusGermany
  4. 4.Abteilung HämatologieKlinikum MindenMindenGermany
  5. 5.St. Antonius-Hospital EschweilerEschweilerGermany
  6. 6.Klinikum ChemnitzChemnitzGermany
  7. 7.Klinik für Innere MedizinUniversitätsklinikum KölnKölnGermany
  8. 8.Innere Medizin IVUniversitätsklinikum HeidelbergHeidelbergGermany
  9. 9.OnkologieMütterhausTrierGermany
  10. 10.IMISELeipzig UniversityLeipzigGermany
  11. 11.DSHNHL SecretariatHomburgGermany

Personalised recommendations